Selective Alpha2 Agonist Reduces Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current alpha2 adrenergic receptor agonists used for treating pain and other conditions often cause undesirable side effects such as hypotension and sedation, and lack specificity for chronic and visceral pain.
Innovation Solution
Development of compounds with specific alpha2 adrenergic receptor agonist activity, such as (+) and (−) enantiomers of 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline and their pharmaceutically acceptable salts or prodrugs, which exhibit selective binding to alpha2 adrenergic receptors, reducing side effects and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective alpha-adrenergic blockers are used, then broad receptor coverage is achieved, but alpha2 receptor mediated side effects (increased plasma catecholamine concentration, increased heart rate, smooth muscle contraction) occur
Solution Approach 1:
The invention segments the alpha-adrenergic receptor blockade by developing compounds with selective affinity for specific alpha receptor subtypes (alpha1A, alpha1B, alpha1D, alpha2A, alpha2B, alpha2C). This allows targeted blockade of specific subtypes while sparing others, thereby achieving the desired therapeutic effect without the side effects caused by non-selective blockade of alpha2 receptors.
Solution Approach 2:
The invention applies local quality by designing compounds with differential binding characteristics to different alpha receptor subtypes. The compounds exhibit varying degrees of selectivity for specific subtypes based on their molecular structure, enabling localized (subtype-specific) pharmacological action rather than uniform blockade across all alpha receptors.
2Reliability
If alpha2 adrenergic receptor agonists are used for pain treatment, then analgesic effect is achieved, but hypotension and sedation occur as side effects
Solution Approach 1:
The invention segments the alpha2 receptor subtype population and develops compounds with selective affinity for specific subtypes (particularly alpha2A and alpha2C). This selective approach maintains the analgesic benefits of alpha2 agonism while reducing the hypotensive and sedative side effects associated with non-selective alpha2 activation.
Solution Approach 2:
The invention changes the selectivity parameter of alpha2 agonism by developing compounds with differential affinity for various alpha2 subtypes. This parameter change (from non-selective to selective agonism) transforms the side effect profile while preserving the therapeutic analgesic effect.
3Reliability
If existing pain treatment compounds are used, then pain relief is provided, but lack of specificity for chronic and visceral pain limits effectiveness
Solution Approach 1:
The invention segments the pain treatment indication into specific types (chronic pain, visceral pain) and develops compounds with selective alpha2 subtype affinity that are particularly effective for these indications. This segmentation allows optimized treatment for specific pain conditions rather than general pain relief.
Solution Approach 2:
The invention enhances universality by developing compounds that can effectively treat multiple types of pain (chronic, visceral, neuropathic) through selective alpha2 subtype agonism, making the treatment more broadly applicable across different pain conditions while maintaining specificity.
Data Source
AI summary
A compound having a structureor a pharmaceutically acceptable salt, or a prodrug thereof is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.